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RESEARCH Open Access
Increased myocardial extracellular volume
in active idiopathic systemic capillary leak
syndrome
Andrew Ertel1,2, Drew Pratt3, Peter Kellman1, Steve Leung1,4, Patricia Bandettini1, Lauren M. Long5, Michael Young5,
Celeste Nelson5, Andrew E. Arai1 and Kirk M. Druey5*
Abstract
Background: The Systemic Capillary Leak Syndrome (SCLS) is a rare disorder of unknown etiology presenting as
recurrent episodes of shock and peripheral edema due to leakage of fluid into soft tissues. Insights into SCLS
pathogenesis are few due to the scarcity of cases, and the etiology of vascular barrier disruption in SCLS is unknown.
Recent advances in cardiovascular magnetic resonance (CMR) allow for the quantitative assessment of the myocardial
extracellular volume (ECV), which can be increased in conditions causing myocardial edema. We hypothesized that
measurement of myocardial ECV may detect myocardial vascular leak in patients with SCLS.
Methods: Fifty-six subjects underwent a standard CMR examination at the NIH Clinical Center from 2009 until 2014: 20
patients with acute intermittent SCLS, six subjects with chronic SCLS, and 30 unaffected controls. Standard volumetric
measurements; late gadolinium enhancement imaging and pre- and post-contrast T1 mapping were performed. ECV
was calculated by calibration of pre- and post-contrast T1 values with blood hematocrit.
Results: Demographics and cardiac parameters were similar in both groups. There was no significant valvular disorder
in either group. Subjects with chronic SCLS had higher pre-contrast myocardial T1 compared to healthy controls
(T1: 1027 ± 44 v. 971 ± 41, respectively; p = 0.03) and higher myocardial ECV than patients with acute intermittent
SCLS or controls: 33.8 ± 4.6, 26.9 ± 2.6, 26 ± 2.4, respectively; p = 0.007 v. acute intermittent; P = 0.0005 v. controls).
When patients with chronic disease were analyzed together with five patients with acute intermittent disease who had
just experienced an acute SCLS flare, ECV values were significantly higher than in subjects with acute intermittent SCLS
in remission or age-matched controls and (31.2 ± 4.6 %, 26.5 ± 2.7 %, 26 ± 2.4 %, respectively; p = 0.01 v. remission,
p = 0.001 v. controls). By contrast, T1 values did not distinguish these three subgroups (1008 ± 40, 978 ± 40, 971 ± 41,
respectively, p = 0.2, active v. remission; p = 0.06 active v. controls). Abundant myocardial edema without evidence of
acute inflammation was detected in cardiac tissue postmortem in one patient.
Conclusions: Patients with active SCLS have significantly higher myocardial ECV than age-matched controls or SCLS
patients in remission, which correlated with histopathological findings in one patient.
Keywords: Systemic capillary leak syndrome, Mycocardial edema, Cardiovascular magnetic resonance
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Background
Patients with SCLS (also known as Clarkson disease) ex-
perience transient but recurring episodes of hypotensive
shock followed by generalized edema of the face, trunk,
and extremities [1]. Although vascular leakage in SCLS
may result from transient, reversible endothelial barrier
dysfunction induced by humoral mediators [2, 3], the
identity of the pathogenic factors and their vascular
target(s) remain unknown. Triggers for SCLS flares are
not apparent although episodes may be preceded by
viral infections, suggesting a role for inflammation in
the induction of acute vascular leak [4]. Because patients
with SCLS feel well between episodes and appear healthy,
it is uncertain whether they have ongoing (subclinical)
vascular barrier dysfunction. The fluid shifts associated
with acute SCLS can lead to cardiopulmonary and renal
failure and compartment syndromes of the extremities,
resulting in chronic sensorimotor defects and loss of
limb(s) [1, 5]. The 5-year mortality due to SCLS in the
absence of prophylactic treatment has been estimated
to be as high as 80 % [4]. However, a longitudinal follow
up study of patients treated prophylactically with high
dose intravenous immunoglobulin (IVIG) on a monthly
basis revealed a significant reduction in the frequency
of SCLS flares compared to pre-IVIG frequencies [6].
A significant obstacle to research into the pathogenesis
of SCLS is the extreme rarity of the disease. Fewer than
300 cases have been reported since its original description
in 1960, and current worldwide prevalence is estimated to
be ~100 cases with a confirmed diagnosis [1]. Because
there are no biomarkers or diagnostic modalities that are
specific to SCLS, the diagnosis is made on the basis of a
triad of clinical signs: hypotension, elevated hematocrit,
and hypoalbuminemia, which are thought to result from
plasma extravasation into tissues. A subset of patients
with SCLS experiences chronic, noncyclical edema and
hypoalbuminemia, which may or may not be accompanied
by periodic hypotensive episodes. It is uncertain whether
these patients have Clarkson disease or a distinct disorder.
Although we hypothesize that the primary vascular
defect in SCLS resides in peripheral tissues, several case
reports have provided evidence of primary myocardial
involvement [7, 8]. A young man with SCLS and
hypotensive shock resistant to fluid resuscitation and
inotropic support was described recently, which required
extracorporeal life support during the leak phase [9].
Echocardiography revealed global left ventricular systolic
dysfunction during the leak phase, and myocardial biopsy
demonstrated extensive interstitial edema without inflam-
matory infiltrates or myocyte necrosis. Systolic function
returned to normal upon resolution of the episode.
Recently, techniques have been described to quantify
the extracellular volume fraction (ECV) of the myocardium
with cardiovascular magnetic resonance (CMR) [10, 11].
Myocardial ECV is increased in conditions in which myo-
cardial tissue is replaced by fibrosis including chronic
myocardial infarction; in conditions causing interstitial
infiltration, such as cardiac amyloidosis; and in conditions
causing interstitial edema, including acute myocardial
infarction and myocarditis [12]. We hypothesized that
ECV measurements would enable detection of myocardial
edema in subjects with active SCLS. Indeed, in a pre-
liminary study, two subjects with chronic SCLS had sig-
nificantly higher ECV values than did a group of 62
healthy controls [13]. In the present study, we quantified
myocardial ECV in an expanded cohort of 26 subjects with
acute, intermittent and chronic forms of SCLS and 30 age-
matched controls without overt cardiovascular disease.
Methods
Patients
Patients were classified with acute intermittent systemic
capillary leak syndrome on the basis of having one or
more episodes associated with the diagnostic clinical
triad of 1) hypotension, 2) elevated hematocrit, and 3)
hypoalbuminemia, using established criteria [4]. Patients
were identified with chronic systemic capillary leak syn-
drome on the basis of having persistent unremitting per-
ipheral edema and hypoalbuminemia in the absence of
any other underlying causes including primary cardiac,
renal, endocrine, or hepatic disease. Control subjects were
defined as individuals undergoing clinically-indicated
contrast-enhanced CMR scans for suspected cardiovascu-
lar disease, whose studies demonstrated normal ventricular
size and systolic function, no significant valvular abnormal-
ities, normal vasodilator perfusion imaging (for patients in
whom stress testing was performed) and an absence of
myocardial enhancement on late gadolinium enhancement
imaging.
Cardiovascular magnetic resonance
Subjects with documented SCLS and control patients
underwent ECV imaging prospectively between 2009 and
2014. Hematocrit was measured from a venous blood sam-
ple obtained immediately prior to the CMR study. The
ECV imaging protocol used in this study was approved
by the local Institutional Review Boards of the National
Heart, Lung and Blood Institute and Suburban Hospital
(Bethesda, MD). All subjects gave written informed con-
sent to participate. CMR was performed with a 1.5 T MRI
scanner (Magnetom Avanto, Espree or Aera, Siemens
Healthcare Sector, Erlanger, Germany) using a 30 or
32-channel coil. Steady-state free precession cine images
(6 mm slice thickness, echo time 1.2 ms, flip angle 50°)
were obtained in short axis view (stack from base to
apex with 4 mm interslice gap) and 3 long axis views
(4-chamber, 3-chamber, 2-chamber). T1 quantification
was performed using a modified Look-Locker inversion-
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recovery (MOLLI) sequence [14] acquired in a mid-
ventricular short axis and a 4-chamber long axis plane
before and approximately 15 min after intravenous admin-
istration of a gadolinium-based contrast agent (0.15 mmol/
kg of either gadopentate dimeglumine [Magnevist®) or
gadobutrol (Gadavist®) (Bayer Healthcare Pharmaceuticals,
Wayne, NJ, USA)]. Typical MOLLI imaging parameters
were: non-selective inversion pulse, steady state free pre-
cession single shot readout with 35° excitation flip angle,
field of view 360 × 270 mm2, slice thickness 6 mm, mini-
mum inversion 110 ms, inversion time increment 80 ms,
matrix 256 × 144, voxel size 2.1 × 1.9 × 6.0 mm3, time to
repetition/time to echo of 2.7/1.1, parallel imaging ac-
celeration with a factor of 2. Both pre- and post-contrast T1
maps were acquired using the same imaging parameters.
Late gadolinium enhancement images were obtained start-
ing approximately 10 min post-gadolinium-administration
using a gradient recalled echo phase-sensitive inversion re-
covery technique (slice thickness 8 mm, echo time: 3.3 ms,
flip angle: 25°) [15]. Optimal inversion time was selected
by review of synthetic magnitude inversion recovery im-
ages generated during a post-contrast MOLLI acquisition
and adjusted as needed to null the myocardium.
ECV quantification
Calculation of the ECV is based on comparison of the
longitudinal relaxation time constant (T1) of myocardium
before and after administration of a gadolinium-based con-
trast agent (GBCA), taking advantage of the properties of
the GBCA, which cannot enter myocardial cells and is thus
exclusively present in the extracellular space. The GBCA
shortens the T1 of the myocardium; thus, any difference in
T1 between pre and post-contrast imaging is related to the
amount of the GBCA in the extracellular space.
Myocardial ECV measurements were generated in one
of two ways, both of which rely on T1 quantification tech-
niques utilizing the MOLLI sequence as described in
detail elsewhere [14]. Briefly, pre- and post-contrast T1
images obtained from the MOLLI sequence were motion-
corrected and reformatted into a pixel map of T1 values. In
our initial approach, average T1 values were quantified from
regions of interest drawn manually within the mid-
ventricular septum and blood pool on both pre-contrast and
post-contrast T1 pixel maps (Fig. 1a). Because the change in
myocardial relaxation rate ΔR1 (where R1 = 1/T1) between
pre and post-contrast is directly proportional to the
extracellular concentration of the GBCA, myocardial ECV
can be estimated as follows (assuming contrast equilib-
rium between blood and myocardium) [10, 11].









The factor (1-hematocrit) represents the blood volume
of distribution of gadolinium (blood ECV) and converts
the equation from a partition coefficient calculation to
the myocardial ECV. Recently, an automated method for
producing a pixel-wise map of ECV has been described
and validated, allowing direct measurement of myocar-
dial ECV [12]. This method relies on co-registration of
the pre- and post-contrast T1 pixel maps, correcting for
respiratory motion due to insufficient breath-holding as
well as patient movement between breath-holds. In this
approach, measurement of ECV was obtained directly
from regions of interest drawn manually within the mid-
ventricular septum on the ECV pixel map.
Histology
Representative samples from the left ventricular free wall,
septum, and right ventricular free wall were fixed in 10 %
neutral buffered formalin, embedded in paraffin and cut
into 5 μm sections. Tissue sections were stained with
hematoxylin and eosin and Masson’s trichrome.
Fig. 1 CMR findings in SCLS. a Pre-and post-contrast T1 maps in the mid-ventricular short axis of a patient with SCLS. Regions of interest drawn
within the septum and blood pool are used to calculate ECV. b Mid-ventricular short axis ECV map in the same patient. The color scale for
displaying ECV values was chosen so that green colors represent the mean ± 3 standard deviations of normal myocardium from age-matched controls
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Immunohistochemical (IHC) staining for CD3 (2GV6,
rabbit monoclonal antibody, Ventana Medical Systems,
Tucson, Arizona, USA) and CD68 (KP-1, Ventana) was
performed and detected by Basic-diaminobenzidine
(DAB) using an automated immunostainer (BenchMark
Ultra, Ventana). Whole slide imaging (WSI) was acquired
using the Aperio digital imaging system (Aperio Scan-
Scope XT scanner; Aperio Technologies, Vista, California,
USA).
Statistical analysis
The data are presented as mean ± s.e.m. unless otherwise
noted. Differences between means were tested by the
Mann-Whitney-U test or Kruskal-Wallis for non-parametric
distributions. P values < 0.05 were considered significant.
Results
Clinical characteristics
We performed CMR in 26 subjects with SCLS and in 30
age-matched control subjects. Amongst the SCLS group,
six patients had a history compatible with chronic SCLS.
Although two of these subjects had a history of acute
SCLS flares characterized by hypotension and hemocon-
centration, they were included in the “chronic” subset
owing to prominent and persistent edema in between
episodes. One subject had atypical disease, with weekly
episodes of hypotension but no peripheral edema that
nonetheless fulfilled the diagnostic criteria for SCLS, and
was therefore included in the analysis of the acute inter-
mittent subgroup [3]. The remaining 19 subjects had
prototypical acute intermittent SCLS as defined previously
[1, 4]. All patients with acute intermittent SCLS did not
have clinical manifestations of vascular leak (e.g. edema)
at the time of CMR examination.
Baseline demographics are reported in Table 1. Parame-
ters (age, sex etc.) did not differ significantly between the
control and SCLS subgroups. At the time of the proced-
ure, 46 % (11/26) of the patients with SCLS were being
treated with theophylline and terbutaline while five sub-
jects were receiving monthly prophylaxis with IVIG. Nine
patients were not receiving any prophylactic therapy prior
to undergoing CMR principally because the diagnosis of
SCLS had not yet been confirmed.
CMR findings
Left ventricular (LV) parameters including end systolic
and diastolic volumes, mass, and ejection fraction were
similar in subjects with acute intermittent SCLS, chronic
SCLS, and controls (Table 2). Quantitative LV volumetric
parameters could not be obtained for one SCLS patient
due to poor image quality. Late gadolinium enhancement
imaging (LGE) was normal in all control patients. In
the SCLS population, one patient had evidence of a
subsegmental myocardial infarction in the apical inferior
wall; one patient had non-diagnostic LGE imaging due to
motion artifact; and three patients had nonspecific atypical
patterns of LGE. Due to the small number of patients with
LGE, a comparison of ECV measurements between SCLS
patients with and without LGE was not performed.
T1 mapping and extracellular volume measurements
Pre-contrast T1 values did not differ significantly be-
tween patients with SCLS and healthy controls overall
(991 ± 42 v. 971 ± 41, p = 0.15). In contrast, myocardial
ECV measurements were significantly higher in the SCLS
cohort than in the control group (28.5 ± 4.2 % vs. 26.0 ±
2.4 %; P = 0.02). ECV values for the patient group overall
were nonetheless within the ± 2 standard deviation (s.d.)
range established in our previous large-scale study of
Table 1 Clinical characteristics of patients undergoing CMR
SCLS acute intermittent SCLS chronic Controls
Number 20 6 30
Age (y)a 51 (40–70) 44 (31–64) 52 (32–77)
Male/Female 13/20 1/6 14/30
Height (cm)b 172 (11) 162 (11) 170 (10)
Weight (kg)b 80 (4) 89 (19) 81 (19)
Body surface area (m2)b 2 (0.2) 2 (0.3) 2 (0.2)
Body mass index (kg/m2)b 27 (4) 33 (5) 28 (5)
Hematocritb 42 (6) 39 (4) 40 (3)
Serum creatinine (mg/dL)b 0.9 (0.2) 0.9 (0.3) 1 (0.2)
Creatinine clearance (mL/min)b,c 105 (36) 129 (30) 93 (34)




dModification of Diet in Renal Disease (MDRD) Study equation
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patients without known cardiac pathology (20.4–30.4 %)
[13]. The highest ECV measurements were found in pa-
tients with noncyclical edema due to chronic SCLS, which
primarily accounted for the statistical difference between
SCLS subjects as a whole and controls. Accordingly, pre-
contrast T1 values were higher in patients with chronic
SCLS than in controls (1027 ± 44 v. 971 ± 41; p = 0.03
(Fig. 2a). ECV values in patients with chronic SCLS were
also significantly higher than in the subset with acute
intermittent SCLS or in the control group [33.8 ± 4.6 %,
26.9.0 ± 2.6 %, 26 ± 2.4 %, respectively; p = 0.007 v. acute
intermittent; p = 0.0005 v. controls] (Fig. 2b). High myo-
cardial ECV was not restricted to those subjects with
chronic, non-cyclical edema, however. ECV values in the
group of patients having what we termed “active” SCLS
(which included both those with chronic edema and
patients with acute intermittent disease, whose CMR
was performed within a month of an acute flare) were
significantly higher than in patients whose disease was
in remission or healthy controls (31.2 ± 4.5 % v. 26.5 ±
2.7 v. 26 ± 2.4; p = 0.001 v. remission, p = 0.001 v. controls)
(Fig. 2c). In contrast, pre-contrast T1 values did not differ
significantly between these three groups (1008 ± 40, 978 ±
40, 971 ± 41, respectively) (Fig. 2d).
We explored whether the combination of T1 and ECV
could discriminate the different patient groups using a
2-dimensional plot. This analysis revealed a great amount
of overlap between the paired T1-ECV points for healthy
control subjects and those with acute intermittent SCLS
(Fig. 3). Values for the chronic SCLS group are shifted up
and to the right of both groups. The dashed line indicates
that it is possible to separate the chronic SCLS group from
normal in all cases in the 2-dimensional analysis, a degree
of separation that is not achieved by T1 or ECV as
Table 2 Cardiac parameters detected by CMR
SCLS acute intermittent SCLS chronic Controls
Left Ventricular (LV) ejection fraction (%)a 62 (5) 66 (8) 64 (5)
LV end diastolic volume (mL)a 145 (36) 153 (23) 144 (33)
LV end systolic volume (mL)a 56 (17) 54 (19) 52 (16)
LV mass (g)a 103 (26) 88 (17) 90 (28)
amean (S.D.)
Fig. 2 Quantitative analysis of pre-contrast T1 and myocardial ECV in SCLS and controls. a–b Pre-contrast myocardial T1 (a) or ECV (b) values were
quantified by CMR in patients with chronic SCLS, acute intermittent SCLS, or controls. T1: *p = 0.03; ECV: **p = 0.007; ***p = 0.0005, Kruskall-Wallis.
c–d ECV (c) or T1 (d) values in patients with active SCLS symptoms regardless of formal classification, patients with periodic disease in remission,
or controls. *p = 0.01; **p = 0.001, Kruskall-Wallis
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individual measurements. That same line separates
chronic SCLS from acute intermittent SCLS in remission
for all but two of the acute intermittent SCLS patients.
Linear discriminate analysis was able to separate the
chronic SCLS group from the combination of healthy
controls and acute intermittent SCLS (p < 0.001). ECV
was a stronger predictor chronic SCLS than native T1
(standardized canonical discriminant function coefficients
0.95 v. 0.11).
Histopathological analysis of myocardial edema
In order to further explore the etiology of increased
myocardial ECV in SCLS, we evaluated postmortem car-
diac tissue from the single patient in the cohort who died
of SCLS during the study period for pathologic features of
edema and/or fibrosis. This patient was a 54-year-old man
who presented with hypotension (systolic blood pressures
in the 80’s), haemoconcentration (Hgb > 20 g/dL), and
hypoalbuminemia (<1.5 g/dL) after experiencing upper
respiratory symptoms for several days. He had presented
similarly 10 years prior to the current episode, at which
time he developed severe edema leading to compartment
syndromes of the arms and legs requiring fasciotomies.
Subsequently, he had experienced only minor episodes of
peripheral edema while receiving prophylaxis with theo-
phylline. Recalcitrant hypotension requiring multiple va-
sopressors, compartment syndromes of the extremities
requiring fasciotomies, and prolonged metabolic acidosis
with multi-organ failure complicated his clinical course.
The patient nearly exsanguinated from fasciotomy site
Fig. 3 Relationship between pre-contrast myocardial T1 and myocardial
ECV. A 2-dimensional analysis of T1 and ECV was performed. Linear
discriminate analysis (dashed line) separates the chronic SCLS group
from the combination of healthy controls and acute intermittent
SCLS (p < 0.001)
Fig. 4 Postmortem histopathologic findings in a patient who died of SCLS. a Low power view of the left ventricle demonstrates diffuse myocardial
edema, as highlighted in the enclosed area. (Masson’s trichrome histochemical stain, 0.6×) (b) Higher power view shows lace-like interstitial fibrosis
between myofibers (Masson’s trichrome, 20×) (c) High power view of myocytes shows marked interstitial edema with an absence of myocyte necrosis
(Hematoxylin and eosin, 20×) Immunohistochemical staining (IHC) for CD3 (d) and CD68 (e) show a paucity of inflammatory cells and the presence of
scattered fibroblasts and few histiocytes. (8×)
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bleeding due to disseminated intravascular coagulation
and eventually developed ischemic necrosis of the right
hand.
Full-thickness sections of the left ventricle from this
patient obtained postmortem demonstrated diffuse edema
within the myocardial wall (Fig. 4a). There was lace-like
fibrosis of the interstitial space in the myocardium, con-
sisted with sustained and/or recurrent, intermittent epi-
sodes of myocardial edema (Fig. 4b). We did not detect
appreciable myocyte necrosis (Fig. 4c) or lymphocytic in-
filtrates (Fig. 4d–e), features that would indicate a primary
inflammatory myocarditis.
Discussion
SCLS is a vastly understudied disorder of unknown etiology,
with few effective therapies, and without specific biomarkers
or diagnostic tests. We hypothesized that myocardial edema
was present in patients with SCLS who have symptoms of
active vascular leakage in peripheral tissues, and we evalu-
ated the utility of myocardial ECV mapping in the diagnosis.
In a cohort of 26 patients with SCLS, myocardial ECV was
significantly higher than in a cohort of age-matched individ-
uals without cardiovascular disease. Myocardial ECV in pa-
tients with the chronic form of SCLS and in patients with
the acute form of SCLS who had had a recent episode
(within 1 month) represented the highest values and largely
accounted for the observed difference. In patients with acute
SCLS in whom there was no recent episode, there was sig-
nificant overlap in ECV measurements between patients
and controls. This finding speaks to the dynamic, reversible
nature of the vascular leak process in SCLS and the need for
early imaging after an acute episode. In point of fact, inter-
episode myocardial ECV was not elevated in our patient
who succumbed to an acute SCLS episode, supporting the
hypothesis that vascular barrier function is largely intact in
subjects with SCLS in remission. Unfortunately, this patient
was too hemodynamically unstable to perform ECV mea-
surements during the acute exacerbation. It is also possible
that subtle defects in vascular barrier function in patients
with subclinical vascular leak may not be discernable by
ECV mapping relative to the ± 2 s.d. range of normal myo-
cardial ECV values (20.4–30.4 %) [12].
Myocardial T1 mapping and ECV mapping have emerged
as promising new techniques, which can complement
conventional cardiac MRI imaging sequences in cases of
homogeneously diffuse myocardial disease states that affect
the myocardial extracellular space. Previous cardiac MRI
techniques have been well validated in the assessment
of focal regions of myocardial fibrosis and edema. Late
gadolinium enhancement imaging is considered the
gold standard for imaging of focal myocardial fibrosis
[16]. T2-weighted imaging techniques have been well
validated in the assessment of focal myocardial edema
in acute myocardial infarction and acute myocarditis
[17]. Both of these techniques, however, rely on signal
intensity differences between normal and abnormal myo-
cardium to define pathology, and are not optimized for
the assessment of diffuse myocardial abnormalities.
T1 and ECV mapping techniques can quantitatively
characterize diffuse myocardial abnormalities not clinic-
ally apparent on LGE or T2-weighted images in a variety
of disease states. T1 and ECV mapping can accurately
detect diffuse increases in the interstitial space due to
infiltrative cardiomyopathies. Recent studies have dem-
onstrated a role for both noncontrast T1 mapping and
ECV mapping in the accurate diagnosis of cardiac amyl-
oidosis [18, 19]. T1 mapping/ECV mapping can also
quantitatively characterize diffuse fibrosis associated with
myocarditis [13], hypertrophic cardiomyopathy [20],
anthracycline cardiotoxicity [21], and non-ischemic
dilated cardiomyopathies [13]. Notably, increased ECV
was also found in patients with systemic sclerosis, a
disorder in which vascular hyperpermeability plays a
role in pathogenesis [22], which was accompanied by
histological evidence of myocardial fibrosis and edema
[23].
The integrity of myocardial vasculature and the overall
contribution of cardiac dysfunction to the protracted
shock associated with acute SCLS episodes are unknown.
In the previously reported patient with histopathological
evidence of myocardial edema, electrocardiogram (ECG)
changes consistent with acute ischemia and elevations of
cardiac troponin I were present transiently [9]. Although
left heart catheterization revealed normal coronary arter-
ies, echocardiography demonstrated increased thickness
of both ventricular walls and globally reduced biventricu-
lar systolic function. By contrast, we found no ECG evi-
dence of ischemia in our patient during the episode, and
cardiac systolic function was reported to be normal by
echocardiography. Thus, further studies will be needed to
determine whether myocardial edema due to fluid leakage
from coronary vessels represents a primary pathome-
chanism of SCLS or develops secondarily as a result of
the multitude of metabolic and/or hematological derange-
ments that typify the course of an acute SCLS attack.
For patients with acute SCLS flares, ECV mapping
could provide a non-invasive quantitative assessment of
the degree of myocardial edema at the time of the study.
This information could serve as a marker for the diagno-
sis of SCLS together with the characteristic laboratory
abnormalities (elevated hemoglobin, hypoalbuminemia)
associated with an acute episode. Serial measurements
of ECV could also serve as markers of treatment efficacy
and/or disease progression. It is worth noting that ap-
proximately 65 % of the patients undergoing CMR in
this study were receiving prophylactic treatment with ei-
ther theophylline-based regimens or IVIG at the time of
the procedure. As we noted, these therapies, in particular
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IVIG, have been shown to induce disease remission in
many patients who receive them [6, 24]. It is possible that
ECV values in the SCLS cohort were skewed by effective
therapy. Given the rarity of this disorder and the inability
to conduct large-scale clinical trials powered for hard
clinical endpoints, ECV measurements could be used
as a surrogate endpoint for studies of pharmacologic ef-
ficacy in the treatment of SCLS.
Unfortunately, the number of patients available for CMR
immediately post-crisis was too small to allow a separate
comparison with subjects with sporadic disease in remis-
sion or a determination of whether a correlation existed
between ECV values and the time since the most recent
episode. Our sample size was also too small to compare
ECV values between treated and untreated patients,
Conclusions
Patients with SCLS have a significantly higher myocardial
ECV than age-matched controls. Elevations in ECV are
most pronounced in patients with a recent SCLS flare or
patients with a chronic form of SCLS. Myocardial ECV
may serve as a diagnostic marker of SCLS and may aid in
the evaluation of future treatments and prognosis in this
rare disorder.
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